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Modern multimodal treatment has significantly increased survival for patients affected by hematologic malignancies, especially
in childhood. Following remission, however, the risk of developing a further malignancy is an important issue. The long-term
estimated risk of developing a sarcoma as a secondarymalignancy is increased severalfold in comparison to the general population.
Ewing’s sarcoma family encompasses a group of highly aggressive, undifferentiated, intra- and extraosseous, mesenchymal tumors,
caused by several types of translocations usually involving the EWSR1 gene. Translocation associated sarcomas, such as Ewing
sarcoma, are only rarely encountered as therapy associated secondary tumors. We describe the clinical course and management of
three patients from a single institution with Ewing’s sarcoma that followed successfully treated lymphoblastic T-cell leukemia or
non-Hodgkin lymphoma. The literature on secondary Ewing’s sarcoma is summarized and possible pathogenic mechanisms are
critically discussed.
1. Introduction
Modern multimodal treatment strategies have significantly
increased the survival of patients affected by hematologic
malignancies, including indolent and aggressive forms of
lymphoma and leukemia [1, 2]. In long-term survivors of
childhood cancer, the risk of a second cancer is an important
issue [3]. Standard treatment for newly diagnosed malignan-
cies varies according to the phenotype, the line of differ-
entiation, biological markers, and extent of the disease and
comprises various combinations of chemotherapy [4], radio-
therapy, targeted therapy with monoclonal antibodies, and
stem cell transplantation, all of which have been implicated
as risk factors for second malignancies. The most common
second cancers reported in this population include cancers
of the head and neck, melanoma, lung cancer, colon cancer,
bladder cancer, renal cancer, Hodgkin disease, leukemia, and
Kaposi sarcoma [5]. Patients who received radiation therapy
are more likely to develop sarcomas, breast cancers, and
mesothelioma compared with patients who have not received
it [5].
Ewing’s sarcoma (ES) is an aggressive malignancy occur-
ring as a primary tumor mostly in adolescents and young
adults with an incidence of about 1/1 000 000, male to female
ratio being 1,5 : 1 [6]. Most cases of ESs (80%) originate in
bones, where this entity comprises the second most common
primary tumor following osteosarcoma in children and ado-
lescents. Up to 20% of primary ESs are located extraosseously
in soft tissues, affecting not only extremities but also various
internal organs [7–10]. ESs are characterized at the molecular
level by the presence of a balanced translocation between the
EWSR1 gene and a member of the ETS gene family, in at least
80% of cases the partner gene being the FLI1 gene (translo-
cation t(11;22) (q24;q12) (EWS-FLI1)) [11]. This molecular
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signature and the clinical characteristics of the patients are
typical for the peripheral primitive neuroectodermal tumor
(PNET) as well. Accordingly, in the current WHO clas-
sification [11], PNET once considered a separate entity is
now considered to represent part of the histologic spectrum
of the “Ewing family of tumors” [6, 12]. The presence of
the fusion gene containing the EWSR1 gene and a member
of the ETS family is the most important tumorigenic fac-
tor in ES; however, recent genomewide association studies
(GWAS) have demonstrated an association of this tumor
with the germline background of the affected patients [13].
These studies provide a plausible explanation for the epi-
demiological finding of a different incidence of ESs across
human populations, for example, the significantly higher
incidence in patients of Caucasian compared to African
origin.
ESs, in contrast to sarcomaswith complex karyotypes and
without recurring genetic aberrations such as osteosarcoma,
have only rarely been reported to occur secondary to can-
cer therapy, including multimodal therapy for hematologic
malignancies [7, 14, 15]. The aim of this study is to analyze
three cases of secondary ES in patients from our institutions
with T-cell leukemia or non-Hodgkin lymphoma (NHL) as
well as summarize documented similar cases from the litera-
ture. In addition, the literature review on Ewing’s sarcoma as
a secondary cancer is summarized and possible pathogenic
mechanisms are critically discussed.
2. Materials and Methods
2.1. Patients. Three patients with a diagnosis of a genetically
confirmed Ewing sarcoma who were previously treated for
leukemia or lymphoma during the period of 1991 to 2014 were
identified among 98 Ewing sarcoma patients in the archives
of the Institute of Surgical Pathology, University Hospital
Zurich, Switzerland. Complete follow-up data were available
for all 3 patients, including information regarding tumor site
and specific treatment modalities of the primary as well as
of the secondary malignancy. The available histopathological
slides of all 3 cases were reviewed to confirm the diagnosis
of ES. A review of the literature published in PUBMED of
previously reported cases of ES following another primary
malignancy was performed.
The study has been carried out according to the ethical
guidelines of our institution.
2.2. Histology and Immunohistochemistry. Tumor tissue sam-
ples were fixed in buffered 4% formalin and embedded in
paraffin. 2𝜇m thick sections were stained with hema-
toxylin and eosin (H&E) according to standard procedures.
Immunohistochemistry (IHC) using the CD99 antibody (di-
lution 1 : 25, clone HO36-1.1, Novocastra Lab Ltd) was per-
formed on 2 𝜇m thick paraffin sections, using the Ventana
Benchmark XT automated staining system (VentanaMedical
Systems, Tucson, Arizona).
2.3. Fluorescence In Situ Hybridization (FISH). Fluores-
cence in situ hybridization (FISH) studies were performed
on formalin-fixed, paraffin-embedded, 4 𝜇m thick tissue
sections as described earlier [16]. Dual color break-apart
FISH detecting translocations involving the EWSR1 (22q11)
gene was performed using commercial probes (Vysis,
Abbott AG, Baar, Switzerland). The SpectrumOrange- and
SpectrumGreen-labeled EWSR1 probes covered 500 kb and
1,100 kb proximal and distal to the EWSR1 gene. The flu-
orescence staining was visualized with an Olympus BX61
microscope (Olympus, Volketswil, Switzerland) equipped
with DAPI, SpectrumGreen and SpectrumOrange filters.
Images were acquired with a CCD camera and processed
with the AnalySIS imaging software (Soft Imagining System,
Munster, Germany). For the assessment of EWSR1 gene
rearrangements at least 50 nonoverlapping tumor nuclei were
analyzed. If the sample contained at least 25% of split red
and green signals, the tumor was regarded as translocation
positive. The signal was considered as split, when red and
green fluorescent spots were separated by at least twice the
distance occupied by a single probe [17].
2.4. RNA Extraction and RT-PCR. To detect EWSR1-FLI1
andEWSR1-ERG fusions transcripts, total RNAwas extracted
form paraffin-embedded tissue as described earlier [18]. Am-
plification was done in a GeneAmp PCR System 9700 (Ap-
plied Biosystems) using an OneStep RT-PCR Kit (Qiagen).
The 25 𝜇L reactions contained 0.4mM dNTP, 1x OneStep
RT-PCR Buffer, 5𝜇L Q-solution, 1 𝜇L enzyme mix (all from
Qiagen), and 8 units of RNase OUT (Life Technologies).
The primer pairs were as follows: (A) TCCTACAGCCAA
GCTCCAAGTC (EWSR1-Ex7b) and ATTCATGTTGGG-
CTTGCTTTTC (FLI1-Ex9); (B) AGAGTAGCTATGGTC-
AACAA (EWSR1-Ex7a) and CCCA(TA)GCTCCTCT
TCTG (FLI1-Ex6); (C) TCCTACAGCCAAGCTCCAAGTC
(EWSR1-Ex7b) andCTCCAGGAGGAACTGCCAAA (ERG-
Ex9).
The reverse transcription was done for 30 minutes at
50∘C, followed by a PCR activation step for 15minutes at 95∘C
and 40 cycles consisting of 1 minute at 94∘C, 1 minute at 56∘C,
and 1 minute at 72∘C followed by final extension at 72∘C for
10 minutes. RNA-integrity was tested by running ACTB- and
IPO8-specific internal control reactions for each sample.
3. Results
3.1. Patients. The basic patient characteristics are summa-
rized in Table 1.
3.1.1. Patient 1. T-cell lymphoblastic non-Hodgkin lym-
phomawas diagnosed in thismale patient at the age of 5 years.
He first presented with supraclavicular swelling. Histopatho-
logic examination of the resected lymph node revealed high
grade T-cell lymphoblastic non-Hodgkin lymphoma (Fig-
ure 1(a); unfortunately, except for the text of the final diagno-
sis and oneH&E slide no further histopathological details are
available). Diagnostic workup including chest and abdominal
CT scans revealed no further tumor manifestations. He
was treated according to the NHL-BFM 90 therapy (Berlin-
Frankfurt-Munster), which comprises cyclophosphamide,
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Table 1: Clinical data on the patients in the current study.
Pat. Gender
Age at
Dx
(T-ALL)
Age at
Dx (ES)
Latency
(y) Location of ES
Treatment of the primary hematological malignancy
Anthracyclines,
TPII-Inh Vinca
Alkylating
agent Antimetabolite RT
1 m 5 8 3 Paravertebral (L5) ADR None CPA, IFO Ara-C None
2 m 16 21 5 Brain, temporal lobe DNR VCR CPA MTX, Ara-C,6-MP, 6-TG
Whole brain
(12 Gy)
3 f 9 11 2 Mandible DNR VCR CPA MTX, Ara-C,6-MP, 6-TG
Whole body
(12 Gy)
DNR, daunorubicin; ADR, doxorubicin; VCR, vincristine; CPA, cyclophosphamide; IFO, ifosfamide; MTX, methotrexate; Ara-C, cytarabine; 6-MP, 6-
mercaptopurine; 6-TG, thioguanine; RT, radiotherapy.
100𝜇m
1mm
(a)
20𝜇m
(b)
EWSR1 (exon 7) FLI1 (exon 6)
C A C C C C C C C C C T T T T T T TC C C CA A AT A A A A A A A A AAG G GAG G G G G G G G G
(c)
Figure 1: (a) Biopsy of the cervical mass of patient 1, 3 years prior to current presentation. Diffuse infiltration of the lymph node tissue with
effacement of the lymph node architecture and spread to the adjacent adipose tissue (star) by sheets of atypical lymphatic blasts (inset) (H&E;
original magnification 400x). (b) Core biopsy of the paravertebral mass of patient 1. Solid small, blue round undifferentiated tumor with
strong immunohistochemical membranous expression of CD99 (brown reaction product shown in the inset) (H&E; original magnification
400x). (c) Sanger-sequencing of the RT-PCR amplicon derived from the fusion transcript reveals the most common EWSR1-FLI1 fusion of
exon 7 to exon 6, respectively, in the paravertebral tumor tissue of patient 1 confirming the diagnosis of a Ewing sarcoma.
dexamethasone, ifosfamide, methotrexate, cytarabine, pred-
nisolone, etoposide, and cyclophosphamide without radio-
therapy. Chemotherapy was completed after 2.5 years in 03/
1998. The patient showed complete remission in the com-
prehensive follow-up investigations that included laboratory
testing, CT scan of brain, chest, and abdomen, bone scan,
bone marrow biopsy, cardiac scan, and renal scan.
Three years after the first presentation, he developed noc-
turnal thigh pain. A bone scan showed a large paravertebral
(level L5) mass. Chest and thorax CT revealed lun metas-
tases. Biopsy of the paravertebral lesion showed a malignant
small, blue, round, cell tumor, histopathologically consistent
with ES (Figure 1(b)). The diagnosis was confirmed by
RT-PCR demonstrating the t(11;22) translocation with the
EWSR1/FLI1 fusion transcript (Figure 1(c)).
The patient received chemotherapy with vincristine, acti-
nomycin, ifosfamide, adriamycin, carboplatin, epirubicin,
and etoposide, based on the CWS-96 protocol (high risk)
[19]. Furthermore, he received radiotherapy to the chest
and paravertebral region with a cumulative dose of 44.8Gy.
Subsequently, CT scans of the chest, abdomen, and spine
revealed complete remission of the pulmonary metastases
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(a) (b)
(c)
Figure 2: (a) Coronary T1 MRI section demonstrating a 4 cm mass (arrow) within the right temporal lobe with middle line shift in patient
2. (b) Biopsy of the intracerebral temporal tumor of patient 2 shows solid small, blue round undifferentiated proliferation with a strong
immunohistochemical membranous expression of CD99 (brown reaction product shown in the inset) (H&E; original magnification 200x).
(c) Fluorescence in situ hybridization (FISH) of the brain tumor of patient 2, demonstrating the rearrangement of the EWSR1 gene.The nuclei
of the tumor cells contain one fused signal (arrow head) and one pair of split green and red signals (arrows).
and size reduction of the left sided paravertebral mass at L4-5
level.
One year later, the patient underwent high dose chem-
otherapy with busulfan and alkeran and autologous stem
cell transplantation. Unfortunately, he developed an infection
with an unknown pathogen one month later that proved
refractory to antibiotic treatment and he died from acute
respiratory distress syndrome.
3.1.2. Patient 2. Acute lymphoblastic T-cell leukemia was
diagnosed in this male patient at the age of 16 years. He
presented with a mediastinal mass without central nervous
system involvement. Bone marrow aspiration showed 95%
blasts infiltration: CD3c+; CD3+; CD4+; CD8+; CD7+;
CD5+; CD34+; CD56+; CD2+; TDT+; TCR a/b+.The patient
underwent chemotherapy with vincristine, daunorubicin,
L-asparaginase, methotrexate (MTX), and Ara-C. Dexam-
ethasone and thioguanine were given during induction and
reinduction. He received whole brain radiation (cumulative
dose 12Gy) and 4 doses of intrathecal therapy with MTX,
prednisolone, and Ara-C. After completion of therapy in
10/2002, the patient showed hematological remission in the
follow-up controls.
Five years and 8months later, the patient presented to the
emergency unit with headache and vomiting. MRI imaging
revealed a large intracerebral tumor mass (Figure 2(a)).
Resection of the tumor revealed a strongly CD99 positive,
small, blue, round cell malignant tumor on histopathological
examination (Figure 2(b)) that lacked the expression of
lymphatic markers. No rearrangement of the TCR-𝛾 gene
locus was found on genotyping. The RT-PCR of the fusion
products of the two most common Ewing sarcoma translo-
cations t(11;22) EWSR1/FLI1 and t(21;22) ESWR1/ERG was
negative; however, FISH analysis revealed the EWSR1 gene
rearrangement (Figure 2(c)), confirming the diagnosis of
Ewing sarcoma and suggesting the presence of one of the rare
ES translocation types.
Postoperatively, radiotherapy with 54Gy was applied to
the right temporoparietal region over 6 weeks. The patient
underwent two cycles of cisplatin and CCNU/lomustine;
however, chemotherapy had to be discontinued in 02/2007
due to myelotoxicity. At the most recent follow-up in 7/2015,
the patient was alive and doing well under anticonvulsive
treatment; however, a small mass was found on control MRI
in the right frontal lobe, suggesting a metastasis.
3.1.3. Patient 3. This female patient developed acute T-
cell leukemia at the age of 9 years. She initially presented
with fatigue accompanied by leukocytosis, mediastinal mass,
and hepatosplenomegaly, but without CNS involvement.
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(a) (b)
(c)
Figure 3: (a) Coronary T1 MRI section demonstrating a large mass (arrow) of the right mandible with infiltration and displacement of the
tongue of patient 3. (b) Biopsy of the intraoral mass of patient 3. Diffuse infiltrates of a small, blue round, undifferentiated tumor with strong
immunohistochemical membranous expression of CD99 (brown reaction product shown in the inset) (H&E; original magnification 100x).
(c) Fluorescence in situ hybridization (FISH) of the jaw tumor of patient 3, demonstrating the rearrangement of the EWSR1 gene. The nuclei
of the tumor cells contain one fused signal (arrow head) and one pair of split green and red signals (arrows).
Cytogenetic analysis of the bone marrow aspiration revealed
t(1;16), loss of TLX3, and biallelic deletion of 12p. The patient
was treated according to the high risk protocol of the ALL-
BFM-2000 trial with prednisone, vincristine, daunorubicin,
L-asparaginase, cyclophosphamide, high dose methotrex-
ate, cytarabine, mercaptopurine, thioguanine, and etoposide.
Due to the risk stratification an allogenic bone marrow
transplantation with an unrelated donor had to be performed
five months after the presentation. Conditioning regimen
included total body irradiation with a cumulative dose of
12Gy (6 × 2Gy), etoposide, and antithymocyte globulin
Fresenius. A graft versus host disease- (GvHD-) prophylaxis
with MTX and cyclosporin A was applied. In the following
controls, she showed an enduring remission.
Two years and four months later, the patient reported a
swelling in the region of the right 2nd lower molar tooth.
MRI of the head (Figure 3(a)) demonstrated a large tumor
mass of the right lower jaw that infiltrated the soft tissues
of the floor of the mouth and displaced the tongue. Biopsy
revealed the diagnosis of Ewing sarcoma with characteristic
small, round, and blue cell histology and typical strong
andmembranous immunohistochemical expression of CD99
protein (Figure 3(b)). This diagnosis was confirmed by the
demonstration of the EWSR1 gene rearrangement on FISH
analysis (Figure 3(c)), with the fusion transcript EWSR1/FLI1
of the diagnostic translocation by RT-PCR (the same type of
the translocation as in patient 1) (Figure 1(c)). The patient
was then treated according to the Euro-Ewing 99 protocol
with vincristine, ifosfamide, doxorubicin, etoposide, acti-
nomycin D, and cyclophosphamide. Local tumor control
was achieved with total tumor resection and mandibular
reconstruction with a fibula plastic. Unfortunately, local
ES recurrence with biopsy confirmation was detected one
year later and the patient underwent radiotherapy with
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a cumulative dose of 54Gy (30 × 1,8 Gy) accompanied by
second-line chemotherapy (cyclophosphamide, topotecan).
Bone metastases in the right femur and fibula were first
diagnosed in the following year, followed by wide metastatic
spread (spine, lung), which prompted renewed chemotherapy
with ifosfamide and palliative mediastinal radiotherapy.
3.2. Review of the Literature. There are only few reports on
ES as a secondary malignancy (Table 2), mostly comprising
single case reports or short series describing ES following
treatment for unrelated tumors, such as breast carcinoma
[20, 21], retinoblastoma [22, 23], or testicular mixed germ cell
tumor [24]. The largest series of secondary ES by Applebaum
et al. [25] evaluated data from the Surveillance, Epidemiology,
and End Results Program (SEER) database between 1973 and
2008 and found 58 cases of secondary ES, accounting for up to
2.1% of all ES. Only 12.1% of patients received radiation to the
ES site, while the frequency of previous chemotherapy is not
reported. Interestingly, five further patients were diagnosed
with ES concurrent with other tumors and were therefore
not included in the study group of “secondary” ES. This
study, however, is purely epidemiological, not including
reevaluation of the diagnoses or molecular confirmation of
ES. The most common group of primary tumors did not
comprise further specified carcinomas (41%: 24 of 58), with
rare cases of non-ES sarcomas, melanomas, brain tumors, or
other neoplasia as a the primary tumor. In 24% (14/58) of
cases in this study, hematological malignancies preceded sec-
ondary ES, representing the second most common primary
malignancy group after carcinomas.
The first case of genetically confirmed ES following a
chemotherapy malignancy (ALL) was described in 1984 by
Tilly et al. [26], although the first case without genetic doc-
umentation was mentioned by Meadows et al. [27] in 1977.
According to the review of available literature, 38 cases
(including the current study) of secondary ES have been
described following the diagnosis of a hematologic malig-
nancy (Table 2); however, confirmatory data on genetic tumor
background (karyotype, FISH, and/or RT-PCR) has been
provided in only 14 cases [14, 26, 28–33].
The diagnosis of secondary ES followed in 1 to 16 years
(mean 6 y) the diagnosis of a hematologic neoplasm, most
often an acute lymphoblastic leukemia (46%: 11 of 24 cases
with available information), Hodgkin lymphoma, or an
aggressive form of non-Hodgkin lymphoma (5 cases (20%)
each). There were only two patients with myelogenous neo-
plasia and 1 with no further specified small cell non-Hodgkin
lymphoma.The age of the patients at the first tumor diagnosis
ranged from 3 to 22 y (mean 10 y) and at ES diagnosis from 7
to 27 y (mean 16 y), with only one substantially older patient
(diagnoses at 57 and 65 y, resp.). All patients with available
data received disease specific chemotherapy for their primary
malignancy, consisting of a combination of various groups
of cytostatic and cytotoxic substances (Table 2) with no
obvious causative association. Secondary ES occurred most
commonly in the chest wall and long bones (7 cases each)
followed by visceral organs (3), pelvis (2), somatic soft tissue
(2), and mandible (1).
4. Discussion
Modern multimodal therapy has led to markedly improved
long-term survival of cancer patients. Concomitantly, a
well-documented increased incidence of malignancies in
cancer survivors in comparison to general population has
been observed. Most cases of secondary tumors can be
attributed to the effects of long-term toxicity of radio-
and/or chemotherapy; however, the underlying mechanisms
of tumorigenesis in this setting remain unclear. In most
instances, nonrandom somatic molecular or chromosomal
alterations are thought to be involved in the pathogenesis
of secondary tumors. Among sarcomas, most therapy asso-
ciated tumors belong to the category of tumors showing
complex karyotypes with mostly nonrecurring genetic aber-
rations, including undifferentiated pleomorphic sarcoma,
osteosarcoma, or rarely malignant peripheral nerve sheath
tumors [41]. Therapy associated angiosarcomas show recur-
rent amplifications of the c-myc gene [42]. Alternatively,
sarcomaswith simple karyotypes, carrying specific transloca-
tions or point mutations, have only rarely been described in
the context of secondary, therapy associated tumors [43].The
underlying pathomechanism of therapy-induced malignan-
cies has been elucidated for only selected secondary tumor
entities. For example, secondary leukemia following the use
of mitoxantrone as an immune modulating drug in patients
with multiple sclerosis has been attributed to inhibition of
topoisomerase II (TI-II) [44, 45]. TI-II inhibition has been
identified as being crucial in the development of the t(15;17)
balanced translocation and generation of the PML-RARalpha
fusion transcript characteristic for promyelocytic leukemia
[46]. Anthracyclines or other drugs inhibiting TI-II are
part of therapeutic regimens for hematologic malignancies
(Table 2); however, it remains to be elucidated whether these
agents play pathogenetically relevant role in the occurrence
of ES as a secondary tumor.
It is well known that immunodeficiency after radio-/
chemotherapy and hematopoietic stem cell transplantation
are major challenges for survivors of hematological malig-
nancies [47, 48]. Impaired antitumor activity of the innate
or adaptive immune system might represent critical factors
that predispose to the failure of the system to detect and
eliminate newly mutated cells carrying the Ewing sarcoma
translocation, thus allowing for the initiation of secondary ES.
Two of the patients described in the current study
received radiation therapy, one total body radiation (TBI)
and one to the site of the ES occurrence (brain), suggesting
a possible role for the radiotherapy in the induction of the
subsequent ES. However, among the data in the literature,
previous irradiation to the ES site was noted in only 12.1%
of the patients in the study of Applebaum et al. [25] and
among the cases compiled in Table 2 with available data on
the previous radiation, there were some patients with TBI (2
of 7), but also patients with no radiation to the body parts
later affected by ES.
The pathogenesis of Ewing sarcoma is strongly linked
to the presence of a translocation between the EWSR1 gene
and a member of the ETS gene family [11]. The occurrence
of the translocation itself was for a long time considered
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to be a random event. In addition, the risk of developing
ES has been linked to increased maternal age [44] and
there are associations with exposure to environmental toxins
[3, 8, 9]. Alternatively, there are striking differences in the
incidence ES according to racial background, ES showing
significantly higher incidence among Caucasians than in
patients of African origin. Recently published observations
[13] of a different frequency of SNPs variants of the EGR2
gene related to Ewing sarcoma susceptibility andmay account
for this observation, since the frequency of the SNP variant
is significantly higher in the non-Africans than in patients
of African origin. This important study provides deeper
insights into the etiology of the occurrence of this specific
translocation associated sarcoma and allows the conclusion
that this is not a random disease but rather the expression of
a germ line predisposition syndrome, thus accounting for the
strong predilection of the Ewing sarcoma to occur in young
patients, similar to other genetically linked tumors.
Due to advances in next generation sequencing tech-
niques and the application of powerful computational tools,
similar germ line association studies (genomewide associa-
tion studies, GWAS) are currently possible on large sets of
genetic data for many tumor types. Germ line associations of
patients with ALL has been recorded for susceptibility, drug
response, and toxicities of ALL therapy [49]. Speculatively, as
yet not identified common genetic predisposition trait may
exist for Ewing sarcoma and some other neoplasia, including
hematologic diseases.
Interestingly, in the recent comprehensive study of germ
line mutations in the best characterized genes associated
with cancer predisposition syndromes in pediatric cancer
patients, 5 patients with relevant mutations (3 patients with
TP53 genemutations, one patients with PMS2 genemutation,
and one patient with RET gene mutation) were identified
among 46 (10.8%) patients with Ewing sarcoma, frequency
of which was higher than in cases of rhabdomyosarcoma
(7%, 3/43) [50]. Ewing sarcoma has been rarely reported
in well-defined germ line mutation associated syndromes
(Cowden syndrome [51], multiple osteochondromatosis [52],
andWilliams syndrome [15]); however it has never been listed
as a syndrome defining entity. Of note, none of the patients
in our study had known cancer predisposition syndromes or
family history of a recognized risk constellation.
According to Sultan et al. [53], 3% of Ewing sarcoma
patients develop secondary tumors (4–9-fold risk compared
to the general population, the risk being higher for children).
In such cases, therapy associated hematologic neoplasms,
radiation associated sarcomas, or carcinomas follow multi-
modal Ewing sarcoma therapy. The relative risk of devel-
oping a second malignancy seems to be higher for Ewing
sarcoma patients in comparison to other tumors (except for
retinoblastoma and primitive neuroectodermal tumors of
the central nervous system), suggesting a relationship of ES
to either aggressive chemotherapy or genetic predisposition,
which may be augmented by the application of cytostatic and
cytotoxic drugs.
In summary, we provide a detailed description of well-
documented cases of Ewing sarcoma following a primary
hematologic malignancy. Additionally we have reviewed the
literature on this association and discussed the possible
pathogenetic aspects. As the survival of cancer patients
will continue to improve in the future, it is important to
understand the risks associated with this success, including
the risk of the development of second malignancies, both
therapy related and/or linked to the genetic background of
the patients.
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